The small-cap dermatology specialist sees accelerating script growth, a step-change in formulary coverage, and a return to positive EBITDA – with the stock up 50% in three months.
DERM · Earnings Call · 2026-08-12
A Launch That's Building Its Own Momentum
Journey Medical's Q2 2026 call made it clear that Amrozi (its oral rosacea therapy) is transitioning from early commercial success to a self-reinforcing growth story. The company reported total revenue of $18.5M, up 23% year-over-year, with Amrozi contributing $8.1M in net revenue. But the real signal is in the prescription metrics: “We continue to make solid progress in our business in the second quarter, as we delivered strong revenue growth and improved profitability during the period.” — Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2026-08-12
Total Amrozi prescriptions reached approximately 36,000 in Q2, up ~20% sequentially from Q1 (which itself grew 11% sequentially). Crucially, growth is now being driven by new prescriptions: “Importantly, the growth is being driven by new prescriptions in addition to refills with successive increases in NRx on a monthly basis.” — Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2026-08-12 The June NRx hit 5.3k, an all-time monthly high, and July continued the trend. The number of unique prescribers jumped to over 4.5k, up from ~3.7k at the end of Q1 and 3.2k at the end of 2025 – a 40% increase in six months. This is exactly the kind of new prescribers adoption that underpins durable growth.
Amrozi was added to the formulary of a major national health plan earlier this month and with other payer initiatives in various stages of progress, we continue to expect our ASP to improve throughout the back half of the year fueling Amrozi sales growth.
Payer Progress: From Access to Quality Coverage
While the company had already locked in all three major GPOs, the second quarter marked a shift from raw access to formulary coverage that actually improves reimbursement. Management reported that the percentage of commercial lives with 'high quality' coverage – defined as a “single step-edit or better” — Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2026-08-12 – rose from 34% in Q1 to 38% currently. This is a direct sequel to the message from the May call, when the company said it was at ~34%: “But when you look at that single step or better, no step, we're looking at about 34% of the 190 million commercial lives.” — Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2026-05-13 The improvement is tangible, and the addition of a large national plan in early August is expected to push it higher.
Ramsey Alloush quantified the remaining friction: “So if you look at the delta between the 2, you are gonna see that, you know, the let's call it 80 to 90 more million lives, right, that potentially have access to Amrozi might have a larger barrier, right, in terms of that friction” — Ramsey Alloush, Chief Operating Officer and General Counsel · 2026-08-12. The company's market access team is focused on converting those lives from 'access' to 'quality coverage', and the sequential improvement in average selling price (ASP) – up again in Q2 after a Q1 gain – validates that this is happening. As fewer prescriptions rely on the co-pay bridging program, gross-to-net should keep improving. The key phrase from the call: “we expect to see good progress from really, from Q4 last year, Q1, to Q2, and our expectation is that we will continue to gain better ASPs as more reimbursement from our payer strategy gets implemented” — Claude Maraoui, Co-Founder, President and Chief Executive Officer · 2026-08-12. This is a recurring, credible theme – the earlier calls (e.g., March) already promised a 'breakthrough year' for Emrosi (as it was then called), a promise that now appears to be materializing.
Financial Inflection: EBITDA Positive, Leverage Building
The most important financial shift is that the company generated positive EBITDA in Q2 and for the first half of 2026. Net loss narrowed to just $0.3M ($0.01 per share) from $3.8M a year ago, and adjusted EBITDA was $2.9M for the quarter. Revenue grew 23% while SG&A actually fell (from $11.9M to $10.9M), demonstrating the operating leverage of the existing commercial infrastructure. This is a company that has historically been loss-making; the revenue series shows steady progress from $13M in Q1 2025 to $16M in Q1 2026, but the Q2 2026 figure of $18.5M (from the call) is the strongest in years outside of the Q3 2023 spike (which included a $20M milestone). The improving mix – Amrozi and Qbrexza are high-margin products – should continue to support gross margin, which held at 67% in Q2.
The stock has responded. After a volatile multi-year history, the recent tape shows a clear breakout: the 90-day return is +49.9%, with the full trend since April 2026 being a sustained rise. This is a genuine 'name in motion' – the market is pricing in the accelerating launch and the path to profitability. The company also hired 5 new sales reps (deployed in July) and launched Urox Cream, a niche anti-itch product, to broaden the portfolio. Management reiterated that 2026 is a 'breakout year' and that they remain focused on Refill rates and new national formulary wins to compound growth. If the payer momentum continues, the ASP gains are additive, and the prescription curve keeps this trajectory, the EBITDA framework could turn sustainably positive – a major shift for a small-cap pharma with a market cap of only ~$170M.